South Texas Pediatric Minority Based CCOP

描述（由申请人提供）：南德克萨斯州儿科少数民族社区临床肿瘤学项目（STP-MB-CCOP）于1990年首次成立，目前已进入第17个资助年，是美国两个单独的儿科CCOP之一。STP-MB-CCOP的主要研究者传统上是位于圣安东尼奥的德克萨斯大学健康科学中心（UTHSCSA）儿科血液学/肿瘤学部门的医生。STP-MB-CCOP作为4个儿科机构的联合体运营：1）CHRISTUS圣罗莎儿童医院（CSRCH）（圣安东尼奥，德克萨斯州）; 2）Drivel儿童医院（Corpus Christi，德克萨斯州）; 3）卫理公会儿童医院（圣安东尼奥，德克萨斯州）; 4）Wilford Hall医疗中心的美国陆军儿科肿瘤学项目（圣安东尼奥，德克萨斯州）。 STP-MB-CCOP将继续为南德克萨斯州受癌症影响的青年人口提供最高标准的护理（即获得临床试验）。此外，它将继续扩大其翅膀方面的人口为基础的研究，处理健康和社会经济问题，具体到南得克萨斯州的人口。 它将针对癌症孤儿（即患有癌症的青少年和年轻人），以了解和消除妨碍他们获得临床试验和生存的障碍。 它将集中精力为居住在下格兰德河山谷的儿科癌症患者提供临床试验。 它将通过解决以下问题进一步评估肥胖对ALL患者生存的影响：1）肥胖的遗传学; 2）肥胖对ALL发展的可能影响; 3）肥胖对肝功能和用于治疗ALL的化疗药物代谢的影响;以及4）肥胖对ALL幸存者后期糖尿病和心血管疾病发展的影响。 它将作为一个临床基础，为遗传学研究的特点，儿童癌症人口在边境人口，包括遗传混合和多态性研究的基因影响癌症的风险和结果。 它将用于开发额外的试点研究，以解决受癌症影响的南德克萨斯州青年人口的独特性（生物或社会经济）。

DESCRIPTION (provided by applicant): The South Texas Pediatric Minority-Based Community Clinical Oncology Program (STP-MB-CCOP) was first formed in 1990, and is currently in its 17th year of funding and is one of two solely pediatric CCOPs in the United States. The Principal Investigator of the STP-MB-CCOP has traditionally been a physician in the Division of Pediatric Hematology/Oncology of the University of Texas Health Science Center at San Antonio (UTHSCSA). The STP-MB-CCOP operates as a consortium of 4 pediatric institutions: 1) CHRISTUS Santa Rosa Children's Hospital (CSRCH) (San Antonio, TX); 2) Driscoll Children's Hospital (Corpus Christi, TX); 3) Methodist Children's Hospital (San Antonio, TX), and 4) the U.S. Army pediatric oncology program at Wilford Hall Medical Center (San Antonio, TX). The STP-MB-CCOP will continue to provide access to the highest standard of care (i.e. access to clinical trials) to the youth population of South Texas affected by cancer. In addition, it will continue to expand its wings in regards to population-based studies dealing with health and socio-economic issues specific to the population of South Texas. It will target the orphans of cancer care delivery (i.e. adolescents and young adults with cancer) in order to understand and abolish the barriers interfering with their access to clinical trials and survival. It will concentrate on bringing access to clinical trials to pediatric cancer patients residing in the Lower Rio Grande Valley. It will further assess the impact of obesity on the survival of ALL patients by addressing issues such as: 1) genetics of obesity; 2) possible impact of obesity on the development of ALL; 3) impact of obesity on liver function and metabolism of chemotherapy agents used to treat ALL; and 4) impact of obesity on later development of diabetes and cardiovascular disease in ALL survivors. It will serve as a clinical base for genetic studies characterizing the pediatric cancer population in border population including genetic admixture and polymorphism studies in genes influencing both cancer risks and outcomes. It will be used to develop additional pilot studies that will address the uniqueness (biologic or socio-economic) of the youth population of South Texas affected by cancer.